Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126250253 | 12625025 | 3 | F | 20160707 | 20160902 | 20160805 | 20160906 | PER | US-PFIZER INC-2016356378 | PFIZER | 42.00 | YR | F | Y | 0.00000 | 20160906 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126250253 | 12625025 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 600 MG, 2X/DAY | Y | 20235 | 600 | MG | BID | ||||||
| 126250253 | 12625025 | 2 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126250253 | 12625025 | 3 | C | GLIPIZIDE. | GLIPIZIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126250253 | 12625025 | 1 | Diabetic neuropathy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126250253 | 12625025 | Drug ineffective for unapproved indication | |
| 126250253 | 12625025 | Fatigue | |
| 126250253 | 12625025 | Feeling abnormal | |
| 126250253 | 12625025 | Sluggishness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126250253 | 12625025 | 1 | 20160707 | 20160801 | 0 |